Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | GPBAR1 | Q8TDU6 | 11/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL876600 | 0.82 | KDM4E (0.57) | KDM4EMAPTGPBAR1CYP1A2CYP3A4 | |
| SCHEMBL881379 | 0.81 | PTGER4 (0.66) | GPBAR1PTGER4 | |
| SCHEMBL876477 | 0.80 | KDM4E (0.61) | KDM4EMAPTGPBAR1 | |
| SCHEMBL877251 | 0.79 | KDM4E (0.75) | KDM4EMAPTGPBAR1CYP1A2CYP3A4 | |
| SCHEMBL876596 | 0.78 | KDM4E (0.58) | KDM4EMAPTGPBAR1CYP1A2CYP3A4 | |
| SCHEMBL877302 | 0.78 | KDM4E (0.58) | KDM4EMAPTGPBAR1CYP1A2CYP3A4 | |
| SCHEMBL15249961 | 0.77 | PTGER4 (0.57) | GPBAR1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL876663 | 0.77 | KDM4E (0.61) | KDM4EMAPTGPBAR1CYP1A2CYP3A4 | |
| SCHEMBL875886 | 0.75 | KDM4E (0.70) | KDM4EMAPTGPBAR1CYP1A2CYP3A4 | |
| SCHEMBL876906 | 0.74 | KDM4E (0.64) | KDM4EMAPTGPBAR1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619182-B1 | PHARMACEUTICAL COMPOSITION | EISAI R&D MAN CO LTD (JP) | 2016-11-09 | — | — | EP | disclosed |
| EP-3061751-A1 | PHARMACEUTICAL COMPOSITION | Eisai R&D Management Co., Ltd. (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-9000024-B2 | Pharmaceutical composition | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20140155452-A1 | PHARMACEUTICAL COMPOSITION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-05 | — | — | US | disclosed |
| US-20130237578-A1 | PHARMACEUTICAL COMPOSITION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-12 | — | — | US | disclosed |
| EP-2619182-A1 | PHARMACEUTICAL COMPOSITION | Eisai R&D Management Co., Ltd. (JP) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012039972-A1 | PHARMACEUTICAL COMPOSITION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155452-A1 | PHARMACEUTICAL COMPOSITION | CYP3A5, CYP2C19, CYP3A7 | KDM4E 3744/4885MAPT 1260/4885GPBAR1 93/4885 |
| US-20130237578-A1 | PHARMACEUTICAL COMPOSITION | CYP3A5, CYP2C19, CYP3A7 | KDM4E 3744/4885MAPT 1260/4885GPBAR1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.